BNGO BIONANO GENOMICS INC

Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City

Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will include presentations from members of the company's leadership team and panel discussions featuring key opinion leaders in basic and clinical research areas including cancer, genetic disorders and cell bioprocessing. Bionano panel members will also participate in a Q&A discussion with the audience.

The event will include a live webcast which will be archived and available for replay after the event. Please visit the "Investors" section of the company website at to register for the webcast and for additional information on the event.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

For more information, visit ,  or 

CONTACTS



Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

Investor Relations:

Amy Conrad

Juniper Point

+1 (858) 366-3243



EN
06/01/2023

Underlying

BNGOBIONANO GENOMICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano to Participate in the H.C. Wainwright @ Home Event

Bionano to Participate in the H.C. Wainwright @ Home Event SAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the H.C. Wainwright @ Home Event on Wednesday, October 15th, 2025. Conference & Webcast Details Date:October 15, 2025Time:10:00 a.m. to 11:00 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:   A replay / recording of the session will be available following the conference through the Bionano website at  for at least 90 days. About ...

October 7, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series ...

September 17, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering

Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series Warrants”), at a combin...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

Multiple Studies Highlighting OGM Utility For Analysis of Cancer Bioma...

Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. According to research, chromoanagenesis refers to a catastrophic ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
BNGO BIONANO GENOMIC...

CMS Posts Preliminary Payment Determination for New Category I CPT Cod...

CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic genome-wide analysis to detec...

September 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch